Entera Bio LTD 10-Q quarterly reports

Entera Bio Ltd. reported its Q2 2026 results, highlighting a substantial $275 million capital raise and progress in its EB613 osteoporosis drug development, alongside increased R&D expenses and continued net losses.

Entera Bio reports Q1 2026 financial results, highlighting progress on its oral peptide pipeline and a $10 million private placement to support Phase 3 development.

Entera Bio Ltd. reported increased operating losses for Q3 and the nine months ended September 30, 2025, despite advancing its oral peptide pipeline and securing new funding through a collaboration with OPKO.

Entera Bio Ltd. reported increased operating losses but secured significant financing and advanced its lead osteoporosis and obesity drug candidates, though substantial doubt remains about its ability to fund future operations.

Entera Bio Ltd. reports its financial results for the first quarter of 2025, highlighting progress in its clinical programs and a new collaboration agreement with OPKO.

Entera Bio's Q3 2024 report shows a net loss of $3.021 million, with ongoing research and development efforts and a focus on oral peptide therapies.

Entera Bio reported a net loss of $4.162 million for the first six months of 2024, while highlighting progress in its oral peptide programs and collaborations.

Entera Bio's first quarter 2024 results show a net loss of $2.017 million, with ongoing development of oral peptide therapies for osteoporosis and hypoparathyroidism.